Forte Biosciences Inc. ( (FBRX) ) has released its Q2 earnings. Here is a breakdown of the information Forte Biosciences Inc. presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Forte Biosciences Inc. is a clinical-stage biopharmaceutical company focused on developing FB102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for autoimmune and autoimmune-related indications, with its headquarters in Dallas, Texas. The company recently released its earnings report for the second quarter of 2025, highlighting significant financial movements and strategic developments. Forte Biosciences reported a net loss of $11.25 million for the three months ended June 30, 2025, compared to a net loss of $12.51 million in the same period in 2024. The company raised $75 million through a public offering, which significantly increased its cash and cash equivalents to $106.1 million as of June 30, 2025, compared to $22.24 million at the end of 2024. This capital infusion is expected to support the advancement of FB102 through clinical trials, including a Phase 2 study for celiac disease and trials for non-segmental vitiligo and alopecia areata. Looking ahead, Forte Biosciences remains focused on its clinical development programs and is poised to continue its research and development efforts, although it anticipates incurring additional losses as it progresses its therapeutic candidates through the pipeline.